A global pharmaceutical company sought to strengthen its insider risk management program to better protect sensitive intellectual property from non‑malicious, malicious, and compromised users. While working to mature its security posture, the organization needed a technology that could enable early risk detection without hindering employee innovation. As a developer of life‑changing medicines, the company faced the challenge of balancing strong data protection with productivity, especially as generative AI tools increased efficiency but also raised the risk of data leakage. High‑fidelity metadata and improved visibility were critical to gaining actionable insights and proactively safeguarding valuable research and IP.

Join for free to read